Jointech Labs

Jointech Labs is an emerging leader in the point-of-care regenerative medicine sector, founded in 2019 and headquartered in San Francisco. Its core technology is the MiniTC® Adipose Processing System, an FDA-cleared, disposable device that enables clinicians to process autologous fat into high-quality microfat for injection in various clinical settings, including orthopedics, sports medicine, and aesthetics. The company is privately held, commercializing its first device while expanding its geographic footprint and clinical applications. Its mission is to advance regenerative therapies into a standard-of-care option for doctors and patients worldwide.

Patented, closed-loop, disposable medical devices for point-of-care processing of autologous adipose tissue into purified microfat and stromal vascular fraction (SVF). The platform emphasizes simplicity, high cell yield/viability, and in-clinic use.

Jointech operates in the competitive point-of-care adipose processing and orthobiologics market, competing against other medical device companies offering closed-system processors for SVF and microfat. Differentiation is based on factors like regulatory status (FDA/CE), cell yield, ease of use, cost, and clinical support. Broader competition includes traditional surgical interventions, steroid injections, and other biologic products like platelet-rich plasma (PRP).